Background: The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.
The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4–ALK-rearranged lung cancer.
The UK's National Institute for Health and Care Excellence (NICE) does not recommend Zykadia (ceritinib) from Novartis, for use in...
Areas covered: The authors review the development and characteristics of brigatinib and discuss the optimal clinical use and sequence of the application of ALK inhibitors in patients progressing under therapy.
Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) may derive significant clinical benefit from targeted therapies against this driver mutation ...
The primary purpose of the study is to compare the antitumor activity of LDK378 versus reference chemotherapy.
Novartis has announced top-line results from its Phase III ASCEND-4 clinical study for Zykadia (ceritinib) in patients with advanced anaplastic...
Novartis has announced that the European Commission has approved Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive...
UK's NICE has announced that Zykadia (ceritinib), from Novartis, has been recommended in line with its marketing authorisation, for the...
The FDA has accepted a new drug application (NDA) seeking the approval of ensartinib (X-396) for the treatment of adult patients with metastatic ALK-positive non–small cell lung cancer (NSCLC), according to an announcement from Xcovery Holdings